Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

M. R. Bristow; H. Krause-Steinrauf; R. Nuzzo; Cheng Seng Liang; J. Lindenfeld; B. D. Lowes; B. Hattler; W. T. Abraham; L. Olson; S. Krueger; S. Thaneemit-Chen; J. M. Hare; H. S. Loeb; M. J. Domanski; E. J. Eichhorn; R. Zelis; P. Lavori

doi:10.1161/01.CIR.0000141297.50027.A4

Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

M. R. Bristow, H. Krause-Steinrauf, R. Nuzzo, Cheng Seng Liang, J. Lindenfeld, B. D. Lowes, B. Hattler, W. T. Abraham, L. Olson, S. Krueger, S. Thaneemit-Chen, J. M. Hare, H. S. Loeb, M. J. Domanski, E. J. Eichhorn, R. Zelis, P. Lavori

School of Medicine

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P

Original language	English (US)
Pages (from-to)	1437-1442
Number of pages	6
Journal	Circulation
Volume	110
Issue number	11
DOIs	https://doi.org/10.1161/01.CIR.0000141297.50027.A4
State	Published - Sep 14 2004

Keywords

Heart failure
Mortality
Nervous system, sympathetic
Risk factors

ASJC Scopus subject areas

Physiology
Cardiology and Cardiovascular Medicine

Access to Document

10.1161/01.CIR.0000141297.50027.A4

Cite this

Bristow, M. R., Krause-Steinrauf, H., Nuzzo, R., Liang, C. S., Lindenfeld, J., Lowes, B. D., Hattler, B., Abraham, W. T., Olson, L., Krueger, S., Thaneemit-Chen, S., Hare, J. M., Loeb, H. S., Domanski, M. J., Eichhorn, E. J., Zelis, R., & Lavori, P. (2004). Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial. Circulation, 110(11), 1437-1442. https://doi.org/10.1161/01.CIR.0000141297.50027.A4

Bristow, MR, Krause-Steinrauf, H, Nuzzo, R, Liang, CS, Lindenfeld, J, Lowes, BD, Hattler, B, Abraham, WT, Olson, L, Krueger, S, Thaneemit-Chen, S, Hare, JM, Loeb, HS, Domanski, MJ, Eichhorn, EJ, Zelis, R & Lavori, P 2004, 'Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial', Circulation, vol. 110, no. 11, pp. 1437-1442. https://doi.org/10.1161/01.CIR.0000141297.50027.A4

@article{b3484a3eba2442be8583ccfa620ad4c9,

title = "Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial",

abstract = "Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P",

keywords = "Heart failure, Mortality, Nervous system, sympathetic, Risk factors",

author = "Bristow, {M. R.} and H. Krause-Steinrauf and R. Nuzzo and Liang, {Cheng Seng} and J. Lindenfeld and Lowes, {B. D.} and B. Hattler and Abraham, {W. T.} and L. Olson and S. Krueger and S. Thaneemit-Chen and Hare, {J. M.} and Loeb, {H. S.} and Domanski, {M. J.} and Eichhorn, {E. J.} and R. Zelis and P. Lavori",

year = "2004",

month = sep,

day = "14",

doi = "10.1161/01.CIR.0000141297.50027.A4",

language = "English (US)",

volume = "110",

pages = "1437--1442",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

AU - Bristow, M. R.

AU - Krause-Steinrauf, H.

AU - Nuzzo, R.

AU - Liang, Cheng Seng

AU - Lindenfeld, J.

AU - Lowes, B. D.

AU - Hattler, B.

AU - Abraham, W. T.

AU - Olson, L.

AU - Krueger, S.

AU - Thaneemit-Chen, S.

AU - Hare, J. M.

AU - Loeb, H. S.

AU - Domanski, M. J.

AU - Eichhorn, E. J.

AU - Zelis, R.

AU - Lavori, P.

PY - 2004/9/14

Y1 - 2004/9/14

N2 - Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P

AB - Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P

KW - Heart failure

KW - Mortality

KW - Nervous system, sympathetic

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=4544318680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544318680&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000141297.50027.A4

DO - 10.1161/01.CIR.0000141297.50027.A4

M3 - Article

C2 - 15337700

AN - SCOPUS:4544318680

SN - 0009-7322

VL - 110

SP - 1437

EP - 1442

JO - Circulation

JF - Circulation

IS - 11

ER -

Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this